ArticleBioinformatics (Oxford, England)2026
Control-guided refinement of partially specified Boolean networks: applications to RTK signaling.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
motivationSystem control can be used to provide new insights into the dynamics of biological systems. A key application is the identification of therapeutic targets in silico, which requires an executable model of the system's dynamics. However, such models are typically underspecified due to incomplete mechanistic knowledge.
resultsWe introduce a novel computational framework that employs control-guided model refinement, predicting informative perturbation experiments to reduce knowledge gaps. The approach is based on partially specified Boolean networks (PSBNs), which enable direct integration of uncertain or incomplete information into executable models. We further extend the framework to handle oscillatory phenotypes as explicit control targets. The applicability of the method is demonstrated on receptor-tyrosine kinase (RTK) signaling, with a focus on fibroblast growth factor signaling in the context of skeletal dysplasias and cancer. We obtain several new insights into modelling of the FGFR3-MAPK pathway. AVAILABILITY AND IMPLEMENTATION: Code and datasets are available at https://doi.org/10.5281/zenodo.16886813.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.